Nucleai to Release Pathology-Based Data at ASCO 2022 for Phase 2 Research in the Most Common Type of Non-Hodgkin’s Lymphoma


CHICAGO–(BUSINESS WIRE)–Nucleai, an AI-powered space biology company whose mission is to transform drug development and clinical treatment decisions by unleashing the power of pathology data, today announced that it will share new data at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in an online publication on an exploratory analysis of a Phase 2 study to find new pathology-based predictive biomarkers for DLBCL, the most common type common non-Hodgkin’s lymphoma. The reunion takes place June 3-7 at Chicago’s McCormick Place.

Up to 40% of patients with DLBCL, which accounts for 30-40% of cases, have relapsed and/or refractory (R/R) disease, despite recent improvements in response and survival with standard treatment. A phase 2 study evaluated the efficacy of naratuximab emtansine, an anti-CD37 ADC, in combination with rituximab, in patients with R/R DLBCL. Deep learning models were used to extract spatial features from scanned slides stained with CD37 and CD20. Their potential as a predictive pathological biomarker of response was assessed.

“The data from our mutual study with Debiopharm is part of our ongoing efforts to enable the next generation of actionable insights from pathology datasets that have not been analyzed to their full potential, but which could provide value. meaningful to pharmaceutical companies and diagnostic laboratories,” said Avi Veidman, CEO of Nucleai. “Nucleai provides a comprehensive solution that combines AI, big data and space biology to discover new biomarkers, predict patient response with higher quality predictive biomarkers, identify new targets and develop the next generation of companion diagnostics based on the pathology.

Nucleai works with most major pharmaceutical companies to harness space biology for new drug development, clinical trials and clinical treatment decisions. Nucleai’s platform is leveraged for retrospective and prospective analysis of patient stratification in clinical trials, resulting in improved likelihood of success and better patient outcomes. By leveraging AI with spatial data and other data modalities, Nucleai enables researchers and clinicians to make better treatment decisions for patients based on a comprehensive and holistic view of cell locations, interactions and the tumor microenvironment.

Nucleai Online Publication at ASCO 2022

  • Title: “Predict the response to naratuximab emtansine, an anti-CD37 antibody-drug conjugate (ADC), in combination with rituximab in diffuse large B-cell lymphoma (DLBCL), by analyzing the spatial arrangement of CD37- and CD20-positive cells ‘deep learning aid’

About Nucleai

Nucleai is an AI-powered space biology company whose mission is to transform drug development and clinical treatment decisions by unleashing the power of disease data. Nucleai provides pharmaceutical companies, contract research organizations and diagnostic laboratories with a state-of-the-art AI platform to improve clinical trials and clinical decision-making. For more information, please visit


Comments are closed.